Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 5, 2003, Pages 371-376

  Abou El Hassan, Mohamed A I ^a   Kedde, Marc A ^a   Zwiers, Ursula T H ^a   Tourn, E ^a   Haenen, Guido R M M ^b   Bast, Aalt ^b   Van Der Vijgh, Wim J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardiotoxicity; Heart; MonoHER; Plasma

Indexed keywords

DOXORUBICIN; FLAVONOID; MONOXERUTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; ELECTROCHEMISTRY; HEART; HEART PROTECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TARGET ORGAN;

ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HYDROXYETHYLRUTOSIDE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; KIDNEY; LIVER; MALE; MICE; MICE, INBRED BALB C; MYOCARDIUM;

EID: 0242329663     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0667-z     Document Type: Article

References (24)

1. Van Acker SABE, Towart R, Husken BCP, De Jong J, Van der Vijgh WJF, Bast A (1993) The protective effect of Venoruton and its main constituents on acute doxorubicin-induced cardiotoxicity. Phlebology Suppl 1:31
2. Haenen GRMM, Jansen FP, Bast A (1993) The antioxidant properties of O-(β-hydroxyethyl)-rutosides of the flavonoid mixture Venoruton. Phlebology Suppl 1:10
3. Van Acker SABE, Boven E, Kuiper K, Van den Berg D, Grimbergen JA, Kramer A, Bast A, Van der Vijgh WJF (1997) Monohyroxyethylrutoside, a dose dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3:1747
4. Van Acker FA, Van Acker SA, Kramer K, Haenen GRMM, Bast A, Van der Vijgh WJF (2000) MonoHER protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6:1337
5. Van Acker SABE, Van den Berg D, Tromp MNJL, Griffioen DH, Van Bennekom WP, Van der Vijgh WJF, Bast A (1996) Structural aspects of the antioxidant activity of flavonoids. Free Radic Biol Med 20:331
6. Van Acker SABE, Van Balen GP, Van den Berg D, Bast A, Van der Vijgh WJF (1998) Influence of iron chelation on the antioxidant activity of flavonoids. Biochem Pharmacol 56:935
7. Barrow A, Griffiths LA (1974) Metabolism of the hydroxyethylrutosides III. The fate of orally administered hydroxyethylrutosides in laboratory animals; metabolism by rat intestinal microflora in vitro. Xenobiotica 4:743
8. Barrow A, Griffiths LA (1974) Metabolism of the hydroxyethylrutosides II. Excretion and metabolism of 3′,4′,7-Tri-O-(β-hydroxyethyl) rutoside and related compounds in laboratory animals after parenteral administration. Xenobiotica 4:1
9. 14C], 7-tetra-O-(β-hydroxyethyl)-rutoside in rats and monkeys after parenteral administration. Xenobiotica 2:575
10. Hollman PCH, van Trijp JMP, Mengerlers MJB, de Vries JHM, Katan MB (1997) Bioavailability of the dietary antioxidant flavonol quercetin in man. Cancer Lett 114:139
11. Griffiths LA, Barrow A (1972) The fate of orally and parenterally administered flavonoids in the mammals. Angiologica 9:162
12. Manach C, Morand C, Texier O, Favier M, Agullo G, Demigne C, Regerat F, Remesy C (1995) Quercetin metabolites in plasma of rats fed diets containing rutin or quercetin. J Nutr 125:1911
13. Griffiths LA, Hackett AM (1978) Hepatic clearance and disposition of hydroxyethylated rutosides. Arch Toxicol Suppl 1:243
14. Abou El Hassan MAI, Kedde MA, Bast A, Van der Vijgh WJF (2001) High performance liquid chromatography with electrochemical detection for the determination of 7-monohydroxyethylrutoside (monoHER) in plasma. J Chromatogr B 752:115
15. Abou El Hassan MAI, Kedde MA, Bast A, Van der Vijgh WJF (2001) Determination of monohydroxyethylrutoside (monoHER) in heart tissue by HPLC with electrochemical detection. J Chromatogr B 757:191
16. UKCCCR (1988) Guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58:109
17. Wienert V, Gahlen W (1970) Renal excretion of trihydroxyethyl rutoside (Venoruton) after parenteral and oral administration. Hautarzt 21:278
18. Ader P, Wessmann A, Wolffram S (2000) Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radic Biol Med 28:1056
19. Korst AEC, Boven E, Van der Sterre MLT, Fichtinger-Schepman AMJ, Van der Vijgh WJF (1998) Pharmacokinetics of cisplatin with and without amifostine in tumor-bearing nude mice. Eur J Cancer 34:412
20. Hackett AM, Griffiths LA (1977) The disposition and metabolism of 3′,4′,7-Tri-O-(β-hydroxyethyl) rutoside and 7-mono-O-(β-hydroxyethyl) rutoside in the mouse. Xenobiotica 7:641
21. Hackett AM, Griffiths LA (1979) The metabolism and excretion of 7-O-(β-hydroxyethyl)-rutoside in the dog. Eur J Drug Metab Pharmacokinet 4:207
22. Ekestroem S, Welti R (1990) The affinity of hydroxyethylrutosides for the venous wall and its efficacy in preventing early occlusions of aorta-coronary vein bypass graft. Phlebology 5 [Suppl 1]:41
23. Neumann HAM, Carlsson K, Brom GH (1992) Uptake and Localization of O-(β-hydroxyethyl) rutosides in the venous wall, measured by laser scanning microscopy. Eur J Clin Pharmacol 43:423
24. Abou El Hassan MAI, Touw D, Wilhelm A, Bast A, Van der Vijgh WJF (2000) Stability of monoHER in an aqueous formulation for i.v. administration. Int J Pharm 211:51